The role of pharmacologic treatment guidelines for bipolar disorder

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 3, 2005, Pages 37-47

  Perlis, Roy H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM CARBONATE; LORAZEPAM; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ALGORITHM; BIPOLAR DISORDER; COMORBIDITY; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; MEDICAL DECISION MAKING; METABOLIC DISORDER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECURRENCE RISK; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; TREATMENT PLANNING; WEIGHT GAIN;

ALGORITHMS; BIPOLAR DISORDER; GREAT BRITAIN; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TEXAS;

EID: 16244402282     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry 2002;159 (suppl 4):1-50
2. Goodwin GM, for the Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149-173
3. Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000;April(Special no.):1-104
4. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63:288-299
5. Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999;60:9-21
6. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? the methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999;281:1900-1905
7. Leibenluft E, Suppes T. Treating bipolar illness: focus on treatment algorithms and management of the sleep-wake cycle. Am J Psychiatry 1999;156:1976-1981
8. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? a framework for improvement. JAMA 1999;282:1458-1465
9. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin Bipolar Disorder Study Group. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000;2:249-255
10. Vieta E, Martinez-Aran A, Nieto E, et al. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000;15:433-437
11. Yatham LN, Kusumakar V, Calabrese JR, et al. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-283
12. Wang PW, Santosa C, Schumacher M, et al. Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 2002;4:296-301
13. Sachs GS. Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol 2003;23(suppl 1):S2-S8
14. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
15. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155-1159
16. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003;64(suppl 5):44-52
17. Suppes T, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000;61(suppl 9):23-30
18. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64:532-539
19. McElroy SL, Keck PE Jr. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000;48:539-557
20. Weisler R, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania. Presented at the American Psychiatric Association 55th Institute on Psychiatric Services; October 29-November 2, 2003; Boston, Mass
21. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-397
22. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155: 128-134
23. Suppes T, Rush AJ, Dennehy EB, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry 2003;64:370-382
24. Goldberg JF. Treatment guidelines: current and future management of bipolar disorder. J Clin Psychiatry 2000;61(suppl 13):12-18
25. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-1033
26. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
27. Strakowski SM, McElroy SL, Keck PE Jr, et al. Suicidality among patients with mixed and manic bipolar disorder. Am J Psychiatry 1996; 153:674-676
28. Calabrese JR, Suppes T, Bowden CL, et al, for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-850
29. Calabrese JR, Bowden CL, Sachs GS, et al, for the Lamictal 602 Study Group. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88
30. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-433
31. El-Mallakh RS, Karippot A. Use of antidepressants to treat depression in bipolar disorder. Psychiatr Serv 2002;53:580-584
32. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-1262
33. Keck PE Jr, Potkin S, Warrington L, et al. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
34. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57
35. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 2003;5(suppl 2):62-79
36. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
37. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997;27:1079-1089
38. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158:420-426
39. Simon NM, Smoller JW, Fava M, et al. Comparing anxiety disorders and anxiety-related traits in bipolar disorder and unipolar depression. J Psychiatr Res 2003;37:187-192
40. Goldberg JF, Garno JL, Leon AC, et al. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999;60:733-740
41. Keck PE Jr, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155:646-652
42. Strakowski SM, DelBello MP, Fleck DE, et al. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000;48:477-485
43. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-181
44. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-690
45. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152:379-384
46. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099-2107
47. Coryell W, Turvey C, Endicott J, et al. Bipolar I affective disorder: predictors of outcome after 15 years. J Affect Disord 1998;50:109-116
48. Keck PE Jr, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997;33:87-91
49. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996;57:292-297
50. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993-1000
51. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21